Prognostic Factors for Cure, Recurrence and Long-Term Survival After Surgical Resection of Thymoma Najib Safieddine, MD, Geoffrey Liu, MD, Kris Cuningham,

Slides:

Advertisements

Similar presentations

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Advertisements

Health-related quality of life in esophageal cancer: Effect of neoadjuvant chemoradiotherapy followed by surgical intervention Najib Safieddine, MD,

Marcelo Cypel, MD, MSc, Jonathan C

Outcomes of intraoperative extracorporeal membrane oxygenation versus cardiopulmonary bypass for lung transplantation Tiago N. Machuca, MD, Stephane.

Sukki Cho, MD, Kyung-Min Ryu, MD, Yoon-Jin Hwang, MD, Eung Bae Lee, MD

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

ALK FISH and IHC: You Cannot Have One without the Other

Long-Term Results after Treatment for Recurrent Thymoma: A Multicenter Analysis Alberto Sandri, Giacomo Cusumano, Filippo Lococo, MD, Marco Alifano, Pierluigi.

Mark F. Berry, MD, Thomas A. Sporn, MD, Joseph O. Moore, MD, Thomas A

A prospective controlled trial of endobronchial ultrasound-guided transbronchial needle aspiration compared with mediastinoscopy for mediastinal lymph.

Andreas Rimner, MD, Daniel R. Gomez, MD, Abraham J

Bronchogenic carcinoma after solid organ transplantation

Invasive Mediastinal Staging Guideline Concordance

Long-Term Outcome after En Bloc Resection of Non–Small-Cell Lung Cancer Invading the Pulmonary Sulcus and Spine Stéphane Collaud, MD, MSc, Thomas K.

Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C

Tumor Regression and Positional Changes in Non-small Cell Lung Cancer During Radical Radiotherapy Gerald Lim, MD, Andrea Bezjak, MD, CM, MSc, Jane Higgins,

Long-Term Outcome After Resection of Non-Small Cell Lung Cancer Invading the Thoracic Inlet Stéphane Collaud, MD, MS, Tiago Machuca, MD, PhD, Olaf Mercier,

Electronic Updates for JTO Readers

Yuzhao Wang, MD, Jonathan C. Yeung, MD, PhD, Waël C

The Impact of Thymoma Histotype on Prognosis in a Worldwide Database

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Surgical Management of Recurrent Thymic Epithelial Tumors: A Retrospective Analysis Based on the Japanese Nationwide Database Tetsuya Mizuno, MD, Meinoshin.

Frank Detterbeck, MD Journal of Thoracic Oncology

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in the Management of Previously Treated Lung Cancer Masaki Anraku, MD, Andrew F. Pierre,

A Combined Prognostic Serum Interleukin-8 and Interleukin-6 Classifier for Stage 1 Lung Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening.

Standard Outcome Measures for Thymic Malignancies

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Clinical Characteristics and Outcomes for Patients With Thymic Carcinoma: Evaluation of Masaoka Staging Anya M. Litvak, MD, Kaitlin Woo, MS, Sara Hayes,

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Treatment of the Elderly When Cure is the Goal: The Influence of Age on Treatment Selection and Efficacy for Stage III Non-small Cell Lung Cancer Linda.

Clinical Outcomes and Prognosis of Recurrent Thymoma Management

Onkar V. Khullar, MD, Yuan Liu, PhD, Theresa Gillespie, PhD, Kristin A

A Prospective Study of Tumor Suppressor Gene Methylation as a Prognostic Biomarker in Surgically Resected Stage I to IIIA Non–Small-Cell Lung Cancers

Stereotactic Body Radiotherapy in Patients with Previous Pneumonectomy: Safety and Efficacy Robert Thompson, MD, Meredith Giuliani, MBBS, Mei Ling Yap,

Referral Patterns for Adjuvant Chemotherapy in Patients with Completely Resected Non-small Cell Lung Cancer Farrah Kassam, MD, Frances A. Shepherd, MD,

Mitotic Inhibitors Journal of Thoracic Oncology

P3-255: Tumor size as a prognostic factor for the survival of surgically treated stage Ia non-small cell carcinoma Gustavo A. Lyons, Silvia Quadrelli,

Mirror Mirror on the Wall, Who Is the Fairest of Them All

High Risk for Thoracotomy but not Thoracoscopic Lobectomy

The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for.

Role of Postoperative Radiotherapy in Nonlocalized Thymoma

Conditional Survival of Malignant Thymoma Using National Population-Based Surveillance, Epidemiology, and End Results (SEER) Registry (1973–2011) Ellen.

Phase I Study of Lenalidomide in Solid Tumors

Video-assisted resection for lung cancer results in fewer complications Lunxu Liu, PhD, MD, FRCS The Journal of Thoracic and Cardiovascular Surgery

Bolstering the Case for Lobectomy in Stages I, II, and IIIA Small-Cell Lung Cancer Using the National Cancer Data Base Susan E. Combs, MA, Jacquelyn.

Gaurav Marwaha, MD, Kevin L. Stephans, MD, Neil M

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Systemic Therapy, Clinical Outcomes, and Overall Survival in Locally Advanced or Metastatic Pulmonary Carcinoid: A Brief Report Patrick M. Forde, MD,

Thymic Carcinoma: A Cohort Study of Patients from the European Society of Thoracic Surgeons Database Enrico Ruffini, MD, Frank Detterbeck, MD, Dirk Van.

International Thymic Malignancies Interest Group: A Way Forward

Risk Factors for Major Complications After Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma Marc de Perrot, MD, Karen McRae, MD, Masaki.

Outcome of Multimodality Treatment for 188 Cases of Type B3 Thymoma

Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma Harvey I. Pass, MD, Chandra Goparaju, PhD, Osvaldo Espin-Garcia,

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

IASLC 6th Latin American Conference on Lung Cancer

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Stage III Thymic Epithelial Neoplasms are Not Homogeneous with Regard to Clinical, Pathological, and Prognostic Features Min-Woong Kang, MD, PhD, Eung-Sirk.

Liseth L. van den Berg, MD, Theo J. Klinkenberg, MD, Harry J. M

Rogerio C. Lilenbaum, MD, John Cashy, PhD, Thomas A

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

The IASLC Lung Cancer Staging Project

A Review of First-Line Treatment for Small-cell Lung Cancer

Outcome after Pulmonary Metastasectomy: Analysis of 5 Years Consecutive Surgical Resections 2002–2006 Kåre Hornbech, MD, Jesper Ravn, MD, Daniel Andreas.

Marcelo Cypel, MD, MSc, Jonathan C

Reply to “Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer: Methodological Issues” Boris Sepesi,

Presentation transcript:

Prognostic Factors for Cure, Recurrence and Long-Term Survival After Surgical Resection of Thymoma Najib Safieddine, MD, Geoffrey Liu, MD, Kris Cuningham, MD, Tsao Ming, MD, David Hwang, MD, Anthony Brade, MD, Andrea Bezjak, MD, Stefan Fischer, MD, Wei Xu, PhD, Sassan Azad, BSc, Marcelo Cypel, MD, Gail Darling, MD, Kazu Yasufuku, MD, Andrew Pierre, MD, Marc de Perrot, MD, Tom Waddell, MD, Shaf Keshavjee, MD Journal of Thoracic Oncology Volume 9, Issue 7, Pages 1018-1022 (July 2014) DOI: 10.1097/JTO.0000000000000215 Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Recurrence-free survival (RFS) by Masaoka stage and World Helath Organization (WHO) histology. A, RFS by Masaoka stage (n = 243). (B) RFS by grouped Masaoka stage (n = 243). (C) RFS by WHO histology (n = 200). Journal of Thoracic Oncology 2014 9, 1018-1022DOI: (10.1097/JTO.0000000000000215) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Recurrence-free survival by tumor size (dichotomized at 7 cm; n = 262) Journal of Thoracic Oncology 2014 9, 1018-1022DOI: (10.1097/JTO.0000000000000215) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions